SGIOY:OTCMKTS
Shionogi & Co.
8,70Â USD
arrow_downward
-0,57%(-0,050) 1G
9 ott, 16:00:00 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per SGIOY in corso…
Apertura
8,75Â USD
Massimo
8,79Â USD
Minimo
8,64Â USD
Cap. mercato
2,44Â Bln
Vol. medio
163,32K
Volume
131,15K
Max 52 sett.
12,00Â USD
Min 52 sett.
7,65Â USD
Beta
0,07
Azioni in circolazione
1,78Â Mld
N. di dipendenti
6K
Apertura
8,75Â USD
Massimo
8,79Â USD
Minimo
8,64Â USD
Cap. mercato
2,44Â Bln
Vol. medio
163,32K
Volume
131,15K
Max 52 sett.
12,00Â USD
Min 52 sett.
7,65Â USD
Beta
0,07
Azioni in circolazione
1,78Â Mld
N. di dipendenti
6K
Articoli giornalistici
Da fonti web e partner giornalistici
Giocare in Borsa Online
·
1 giorno fa
Dell batte l’S&P 500: ritorno annuo al 65% in cinque anni
www.giocareinborsa.com
·
2 ore fa
Wall Street aspetta ASML e Taiwan Semi: S&P 500 vicino ai massimi
Investire.biz
·
3 ore fa
Utili S&P 500 nel terzo trimestre: FactSet stima un +30%
Profilo
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Informazioni su Shionogi & Co.